Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation: A Meta-Analysis of Placebo-Controlled Randomized Trials
The DOI matches its Crossref record, with a small difference in title or year; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antidepressants are effective in the prevention of relapse after remission from an acute depressive episode. It is unclear, however, to what degree duration of the continuation phase, level of abruptness of antidepressant discontinuation, or the number of previous episodes moderate the prophylactic effect of antidepressants. DATA SOURCES: Searches were conducted to identify all published randomized, placebo-controlled, double-blind clinical trials available for review by May 2007 on the efficacy of continuation or maintenance treatment of major depressive disorder with either selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs) that included patients entering a maintenance phase after achieving remission from the acute phase. The MEDLINE and EMBASE databases were searched using the terms depression, antidepressants, discontinuation, and maintenance treatment; this was followed by reference checks of articles thus identified. In addition, the Cochrane Library was also searched using the same terms. Some authors of the identified papers were contacted for specific data. DATA SYNTHESIS: Data were collected from 30 trials with 4890 participating patients. The overall reduction of relapse risk in the maintenance phase was highly significant for both SSRIs (OR = 0.24, 95% CI = 0.20 to 0.29) and TCAs (OR = 0.29, 95% CI = 0.23 to 0.38) over 1 year of follow-up of maintenance treatment. The prophylactic effect appeared to be constant over the length of the continuation phase. Recurrent episode patients experienced less protection from antidepressants over the maintenance phase (OR = 0.37, 95% CI = 0.31 to 0.44) than single episode patients (OR = 0.12, 95% CI = 0.06 to 0.26). CONCLUSIONS: Antidepressants robustly reduce relapse risk in the maintenance phase, regardless of a number of clinical and pharmacologic factors. There is evidence, however, that with increasing number of episodes, patients develop a relative resistance against the prophylactic properties of antidepressant medication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaymaz et al. (2008) came to the diametrically opposed conclusion, finding that an increasing number of prior episodes instead reduced the prophylactic effect of antidepressants.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Antidepressant medications (ADM) have proven utility not only in treating acute episodes of depression, but also in reducing the risk of relapse (Geddes et al. 2003; Kaymaz et al. 2008; Glue et al. 2010; Sim et al. 2015).”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Using a meta-regression approach, they later found that the odds ratio for relapse after discontinuation compared with continuation in first-episode patients was 0.12, while it was 0.31 in patients in their second or more episodes.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Several meta-analyses (Viguera et al. 1998; Geddes et al. 2003; Kaymaz et al. 2008; Glue et al. 2010; Andrews et al. 2011) have, however, examined it, with none finding a significant effect.”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Kaymaz et al. 2008
In the citing paper
“Several systematic reviews of studies have shown a higher rate of relapse among patients who discontinue antidepressant therapy than among those who continue to receive such therapy”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [7]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779 · cited 1×
“Another limitation is that our results may be subject to publication bias as negative trials are more likely to remain unpublished.(72) This is a general limitation of any conclusion based on perusal of the literature.”
BackgroundFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“In 1988, the MacArthur Foundation Research Network on the Psychobiology of Depression convened a task force to examine the ways in which change points in the course of depressive illness until that time had been described and the extent to which inconsistencies in these descriptions might hinder research on this disor…”
BackgroundThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297 · cited 1×
“Number of Previous Depressive Episodes A history of severe and frequently recurring depressive episodes is considered to be a plausible clinical predictor of increased risk of relapse or recurrences after discontinuation of the antidepressant.(22,26,55) Regarding the second question (of whether treatment should be con…”
ResultRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“In a 2003 meta-analysis of 31 randomized trials (4410 participants), Geddes et al.(6) showed that continuing antidepressant therapy consistently reduced the risk of relapse and recurrence by 70% compared with continuation with placebo, and this seemed to be similar for all classes of antidepressants.”
BackgroundReynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Spijker, J., De Graaf, R., Bijl, R. V., Beekman, A. T. F., Ormel, J., & Nolen, W. A. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.3.208 · Cited by 514 · cited 1×
“tients experience a chronic course, and 75% to 80% of patients experience recurrent episodes.(1,2) Therefore, treatment should focus not only on improving symptoms of the acute episode but also on the prevention of relapse (return of symptoms of the index episode) and recurrence (the development of a subsequent episod…”
BackgroundTreatment of Depression by Drugs and Psychotherapy
KLERMAN, G. L., DIMASCIO, A., WEISSMAN, M., PRUSOFF, B., & PAYKEL, E. S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.2.186 · Cited by 500
Executive Dysfunction and Long-term Outcomes of Geriatric Depression
Alexopoulos, G. S., Meyers, B. S., Young, R. C., Kalayam, B., Kakuma, T., Gabrielle, M., Sirey, J. A., & Hull, J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.285 · Cited by 486
Angst, J. (1992) · Psychopharmacology · doi:10.1007/bf02246240 · Cited by 409 · cited 1×
“tients experience a chronic course, and 75% to 80% of patients experience recurrent episodes.(1,2) Therefore, treatment should focus not only on improving symptoms of the acute episode but also on the prevention of relapse (return of symptoms of the index episode) and recurrence (the development of a subsequent episod…”
Background
Cited by
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
“In particular, recurrent depressions are more difcult to treat than first-episode depressions (O’Reardon et al., 007; Souery et al., 2007; Kaymaz et al., 2008; Rush et al., 011).”
BackgroundPrevalence and predictors of recurrence of major depressive disorder in the adult population
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W. A., & Beekman, A. T. F. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01519.x · Cited by 486
“The risk of relapse or recurrence by maintenance treatment with antidepressants can be reduced by 25% when compared with placebo (39, 40).”
BackgroundBockting, C. L., Hollon, S. D., Jarrett, R. B., Kuyken, W., & Dobson, K. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.02.003 · Cited by 295
“If this prescriptive finding holds with preventive psychological interventions, it will be particularly important since continuation phase ADM appears to be less effective in preventing relapse/ recurrence for the patients with the higher risks (Kaymaz et al., 2008).”
BackgroundIsingrini, E., Camus, V., Le Guisquet, A.-M., Pingaud, M., Devers, S., & Belzung, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010404 · Cited by 277
“Finally, it seems that an increased number of past depressive episodes can also be associated with resistance to AD [14,15].”
BackgroundMore treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Packages of care for depression in low- and middle-income countries
Patel, V., Simon, G., Chowdhary, N., Kaaya, S., & Araya, R. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000159 · Cited by 202
“Following a therapeutic response, antidepressant continuation treatment for a period of 9 to 12 mo has been found to significantly reduce the risk of relapse/recurrence [30].”
BackgroundMaintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192
Wichers, M., Peeters, F., Geschwind, N., Jacobs, N., Simons, C. J. P., Derom, C., Thiery, E., Delespaul, P. H., & van Os, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.11.010 · Cited by 189
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W. A., & Beekman, A. T. F. (2013) · Psychological Medicine · doi:10.1017/s0033291712002395 · Cited by 176
“Clinicians should be aware of these risk factors and consider long-term treatment with antidepressants (Geddes et al. 2003; Kaymaz et al. 2008) or additional psychological treatment, for example preventive cognitive therapy (Bockting et al.”
BackgroundInfluentialBiesheuvel-Leliefeld, K. E. M., Kok, G. D., Bockting, C. L. H., Cuijpers, P., Hollon, S. D., van Marwijk, H. W. J., & Smit, F. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.016 · Cited by 175
“…is under debate as the optimal duration of the continuation- or maintenance phase has not been studied well enough (Geddes et al., 2003; Kaymaz et al., 2008), there is divergent information about discontinuation of continuation- or maintenance ADM and the relation to relapse or…”
Stangier, U., Hilling, C., Heidenreich, T., Risch, A. K., Barocka, A., Schlösser, R., Kronfeld, K., Ruckes, C., Berger, H., Röschke, J., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060734 · Cited by 174
Guidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“A recent meta-analysis (Kaymaz et al., 2008) has indicated that antidepressants reduce the relapse risk in the maintenance phase.”
Treatment-resistant depression: are animal models of depression fit for purpose?
Willner, P., & Belzung, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4034-7 · Cited by 164
“Recurrent depressions are also more resistant to pharmacotherapy than first-episode depressions (O’Reardon et al. 2007; Souery et al. 2007; Kaymaz et al. 2008; Rush et al. 2011).”
BackgroundLu, Y., Liang, H., Han, D., Mo, Y., Li, Z., Cheng, Y., Xu, X., Shen, Z., Tan, C., Zhao, W., et al. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.04.008 · Cited by 144
“Early studies suggested that psychological treatments earlier in life and at earlier stages of illness reduced the rate of recurrence of depressive episodes (Kaymaz et al., 2008).”
BackgroundNeurobiological correlates of illness progression in the recurrent affective disorders
Post, R. M., Fleming, J., & Kapczinski, F. P. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.02.004 · Cited by 159
Kok, R. M., Heeren, T. J., & Nolen, W. A. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ec8085 · Cited by 141
Molecular aspects of depression: A review from neurobiology to treatment
Villas Boas, G. R., Boerngen de Lacerda, R., Paes, M. M., Gubert, P., Almeida, W. L. D. C., Rescia, V. C., de Carvalho, P. M. G., de Carvalho, A. A. V., & Oesterreich, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.024 · Cited by 128
Bockting, C. L. H., Klein, N. S., Elgersma, H. J., van Rijsbergen, G. D., Slofstra, C., Ormel, J., Buskens, E., Dekker, J., de Jong, P. J., Nolen, W. A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30100-7 · Cited by 130
Berwian, I. M., Wenzel, J. G., Collins, A. G. E., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4971 · Cited by 113
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
“Current maintenance therapy guidelines are based primarily on prior meta-analyses that have found that the relapse rates in the Drug–Drug arms of ADM discontinuation studies are consistently lower than in the Drug–Placebo arms (Viguera et al., 1998; Geddes et al., 2003; Kaymaz et al., 2008; Glue et al., 2010).”
BackgroundMethodResultInfluentialOrmel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
“In addition, some recurrences after the switch from antidepressant to placebo might actually have been withdrawal or rebound phenomena as these frequently occur within 3–6 months after discontinuation [32,42,43].”
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Hardeveld, F., Spijker, J., De Graaf, R., Hendriks, S. M., Licht, C. M. M., Nolen, W. A., Penninx, B. W. J. H., & Beekman, A. T. F. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.008 · Cited by 95
“However, aside from pharmacological treatment (Kaymaz et al., 2008), other programmes to prevent recurrence, e.g. mindfulness-based cognitive therapy (Piet and Hougaard, 2011) and cognitive therapy (Beshai et al., 2011) are mainly carried out in specialized mental health care.”
BackgroundRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Al-Karawi, D., Al Mamoori, D. A., & Tayyar, Y. (2016) · Phytotherapy Research · doi:10.1002/ptr.5524 · Cited by 91
“These recommendations are still under debate concerning the optimal duration of maintenance, which has not yet been thoroughly investigated (Kaymaz et al., 2008).”
BackgroundHöhn, P., Menne-Lothmann, C., Peeters, F., Nicolson, N. A., Jacobs, N., Derom, C., Thiery, E., van Os, J., & Wichers, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075655 · Cited by 86
“response [32].”
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
“While Viguera et al. (1998) found that patients with more prior episodes benefited more from antidepressant treatment, Kaymaz et al. (2008) came to the diametrically opposed conclusion, finding that an increasing number of prior episodes instead reduced the prophylactic effect of antidepressants.”
BackgroundResultInfluentialReid, S., & Barbui, C. (2010) · BMJ · doi:10.1136/bmj.c1468 · Cited by 93
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Pharmacotherapy of postpartum depression: an update
Kim, D. R., Epperson, C. N., Weiss, A. R., & Wisner, K. L. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.911842 · Cited by 73
“Based on the general depression treatment guidelines, women should be continued for at least 9 -- 12 months once they have achieved remission of symptoms [84,85].”
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
The rise of mindfulness and its resonance with the Islamic tradition
Thomas, J., Furber, S. W., & Grey, I. (2017) · Mental Health, Religion & Culture · doi:10.1080/13674676.2017.1412410 · Cited by 62
Rush, A. J., Wisniewski, S. R., Zisook, S., Fava, M., Sung, S. C., Haley, C. L., Chan, H. N., Gilmer, W. S., Warden, D., Nierenberg, A. A., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711002170 · Cited by 65
“Despite growing research interest in understanding the impact of prior course on longer-term outcomes (e.g. Kaymaz et al. 2008 ; Pettit et al. 2009 ; Klein, 2010), few studies have attempted to fully examine the extent to which recurrence and/or chronicity affect treatment outcomes in…”
BackgroundHuijbers, M. J., Spinhoven, P., Spijker, J., Ruhé, H. G., van Schaik, D. J. F., van Oppen, P., Nolen, W. A., Ormel, J., Kuyken, W., van der Wilt, G. J., et al. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.168971 · Cited by 58
Lako, I. M., Taxis, K., Bruggeman, R., Knegtering, H., Burger, H., Wiersma, D., & Slooff, C. J. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.10.007 · Cited by 53
“Their antidepressant therapy may have served as an effective prophylaxis [16,21], for other indications such as negative symptoms or anxiety or it may indicate overprescribing.”
BackgroundDepression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 56
Guidelines for the diagnosis and treatment of depressive disorders in China: The second edition
Feng, Y., Xiao, L., Wang, W., Ungvari, G. S., Ng, C. H., Wang, G., & Xiang, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.104 · Cited by 51
Bockting, C., Smid, N. H., Koeter, M. W. J., Spinhoven, P., Beck, A. T., & Schene, A. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.048 · Cited by 56
“Reported reduction of the risk of recurrence compared to placebo are odds ratios ranging from 0.12 to 0.35 (Geddes et al., 2003; Kaymaz et al., 2008; Hansen et al., 2008; Glue et al., 2010).”
InfluentialPiek, E., van der Meer, K., & Nolen, W. A. (2010) · European Journal of General Practice · doi:10.3109/13814781003692463 · Cited by 45
Huijbers, M. J., Spinhoven, P., Spijker, J., Ruhé, H. G., van Schaik, D. J. F., van Oppen, P., Nolen, W. A., Ormel, J., Kuyken, W., van der Wilt, G. J., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.023 · Cited by 43
“The most common strategy to prevent relapse/recurrence after a depressive episode is maintenance antidepressant medication (mADM), which has been found more effective than placebo (Kaymaz et al., 2008).”
BackgroundFregni, F., Brunoni, & Jr, F. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5751 · Cited by 40
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Cross-species evidence for the role of interleukin-33 in depression risk.
Kudinova, A. Y., Deak, T., Hueston, C. M., McGeary, J. E., Knopik, V. S., Palmer, R. H. C., & Gibb, B. E. (2016) · Journal of Abnormal Psychology · doi:10.1037/abn0000158 · Cited by 39
Willner, P., Scheel-Krüger, J., & Belzung, C. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000066 · Cited by 36
“In addition to being more readily precipitated by lower levels of stress, recurrent depressions are more difficult to treat than first-episode depressions (O’Reardon et al., 2007; Souery et al., 2007; Kaymaz et al., 2008; Rush et al., 2011).”
BackgroundTreatment Selection in Depression: The Role of Clinical Judgment
Tomba, E., & Fava, G. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.003 · Cited by 35
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
Rucci, P., Frank, E., Calugi, S., Miniati, M., Benvenuti, A., Wallace, M., Fagiolini, A., Maggi, L., Kupfer, D. J., & Cassano, G. B. (2011) · Depression and Anxiety · doi:10.1002/da.20894 · Cited by 33
Mocking, R. J. T., Figueroa, C. A., Rive, M. M., Geugies, H., Servaas, M. N., Assies, J., Koeter, M. W. J., Vaz, F. M., Wichers, M., van Straalen, J. P., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009510 · Cited by 31
Biesheuvel-Leliefeld, K. E. M., Dijkstra-Kersten, S. M. A., van Schaik, D. J. F., van Marwijk, H. W. J., Smit, F., van der Horst, H. E., & Bockting, C. L. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000472260 · Cited by 29
“The recommendations on ADM are under debate [12] as the optimal duration of the continuation or maintenance phase has not been studied well enough [9, 11] .”
Stimpfl, J. N., Walkup, J. T., Robb, A. S., Alford, A. E., Stahl, S. M., McCracken, J. T., Stancil, S. L., Ramsey, L. B., Emslie, G. J., & Strawn, J. R. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0099 · Cited by 32
“…dose (Fava et al., 2015; Horowitz and Taylor, 2019), duration of treatment, use for recurrent mood disorders (compared with single episodes) (Kaymaz et al., 2008), anti-depressant half-life, pharmacodynamic pro fi le (Dilsaver et al., 1983), and rate of discontinuation (Tint et al., 2008)…”
Bockting, C. L., Elgersma, H. J., van Rijsbergen, G. D., de Jonge, P., Ormel, J., Buskens, E., Stant, A. D., de Jong, P. J., Peeters, F. P., Huibers, M. J., et al. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-8 · Cited by 29
“Meta-analyses indicate that cognitive therapy (CT) is not only an effective treatment of MDD, but can also be used as an effective preventive intervention [10-17].”
BackgroundMethodBerwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Kasper, L., Veer, I. M., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-79170-9 · Cited by 29
Mindfulness-based stress reduction among Emirati Muslim women
Thomas, J., Raynor, M., & Bakker, M.-C. (2016) · Mental Health, Religion & Culture · doi:10.1080/13674676.2016.1168389 · Cited by 28
Gili, M., Vicens, C., Roca, M., Andersen, P., & McMillan, D. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.07.035 · Cited by 35
Cosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
“041 Practice nurse Baseline 233 6 (13) 237 6 (11) 6 months 233 10 (17) 237 10 (16) 12 months 233 10 (17) 237 9 (16) Total 233 20 (28) 237 19 (28) –1.”
Meyer, A., Bress, J. N., Hajcak, G., & Gibb, B. E. (2016) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2016.1138405 · Cited by 25
Stress Reactivity, Depressive Symptoms, and Mindfulness: A Gulf Arab Perspective
Thomas, J., Raynor, M., & Bahussain, E. (2016) · International Perspectives in Psychology · doi:10.1037/ipp0000055 · Cited by 26
Maintenance use of antidepressants in Dutch general practice: non-guideline concordant
Piek, E., Kollen, B. J., van der Meer, K., Penninx, B. W. J. H., & Nolen, W. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097463 · Cited by 24
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
The antidepressant standoff: Why it continues and how to resolve it
Ormel, J., Spinhoven, P., de Vries, Y. A., Cramer, A. O. J., Siegle, G. J., Bockting, C. L. H., & Hollon, S. D. (2020) · Psychological Medicine · doi:10.1017/s0033291719003295 · Cited by 22
“Its bias potential is unclear because of uncertainty about the risk period of withdrawal phenomena (Borges et al., 2014; El-Mallakh, Waltrip, & Peters, 1999; Kaymaz et al., 2008).”
Duffy, L., Bacon, F., Clarke, C. S., Donkor, Y., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., King, M., et al. (2019) · Trials · doi:10.1186/s13063-019-3390-8 · Cited by 22
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
“Given that a decrease in the effect of antidepressants has also been reported during continuous antidepressant use [3–7], with repeated exposures [8–10], and in patients with recurrent episodes [49], it is possible that these different types of response failures reflect a broader phenomenon.”
BackgroundDrug Approval and Drug Effectiveness
Spielmans, G. I., & Kirsch, I. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185533 · Cited by 23
“However, the relative advantage for antidepressants plateaued at 3 months, with the later follow-up periods finding no additional benefit beyond what had been achieved in the first 90 days (Kaymaz et al. 2008).”
BackgroundLü, Y., Shen, Z., Cheng, Y., Yang, H., He, B., Xie, Y., Wen, L., Zhang, Z., Sun, X., Zhao, W. D., et al. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00205 · Cited by 21
“Earlier treatments could help to reduce the recurrence rate of depression (8).”
BackgroundWagner, G. J., McBain, R. K., Akena, D. H., Ngo, V. K., Nakigudde, J., Nakku, J. E. M., Chemusto, H., Beyeza‐Kashesya, J., Gwokyalya, V., Faherty, L. J., et al. (2019) · Medicine · doi:10.1097/md.0000000000016329 · Cited by 21
“considered if symptoms are in remission (PHQ-9 <5) for 6 months,([46]) and if the client is at least 6months past completion of pregnancy, given the heightened risk of depression post-partum and in the event that there’s a miscarriage or abortion.”
BackgroundMari, J. D. J., Tófoli, L. F., Noto, C. D. S., Li, L. M., Diehl, A., Claudino, A. M., & Juruena, M. F. (2013) · Drugs · doi:10.1007/s40265-013-0113-4 · Cited by 23
“Following a therapeutic response, AD continuation treatment for a period of 9–12 months has been found to significantly reduce the risk of a new episode relapse [94].”
BackgroundKudinova, A. Y., Burkhouse, K. L., Siegle, G. J., Owens, M., Woody, M. L., & Gibb, B. E. (2016) · Psychophysiology · doi:10.1111/psyp.12764 · Cited by 21
Huijbers, M. J., Spinhoven, P., van Schaik, A., Nolen, W. A., & Speckens, A. E. M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.041 · Cited by 20
“number of previous episodes (Kaymaz et al., 2008).”
Amygdala Reactivity, Antidepressant Discontinuation, and Relapse
Erdmann, T., Berwian, I. M., Stephan, K. E., Seifritz, E., Walter, H., & Huys, Q. J. M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.2136 · Cited by 18
Medicinal Plants in the Treatment of Depression. II: Evidence from Clinical Trials
Moragrega, I., & Ríos, J. L. (2021) · Planta Medica · doi:10.1055/a-1517-6882 · Cited by 22
“In addition, various studies have also reported on the existence of a dysfunction of the HPA axis underlying depressive disorders, as well as the role of corticosteroids through the release of the corresponding hormones, such as the CRH in the paraventricular nucleus of the hypothalamus, the ACTH in the pituitary glan…”
Background(2024) · doi:10.1016/j.psychres.2024.115926 · Cited by 15
Gülpen, J., Breedvelt, J., van Dis, E. A. M., Geurtsen, G. J., Warren, F. C., Heeringen, C. V., Hitchcock, C., Holländare, F., Huijbers, M. J., Jarrett, R. B., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291725000157 · Cited by 18
“Moreover, patients prefer psychological treatment (McHugh et al., 2013), experience side effects from ADM (Anderson et al., 2012; Ferguson, 2001), and can resist prophylactic properties with long-term usage (Kaymaz et al., 2008), underscoring the limitations of relying solely on ADM.”
Biesheuvel-Leliefeld, K. E. M., Dijkstra‐Kersten, S. M. A., van der Horst, H. E., van Schaik, A., Bockting, C., Bosmans, J. E., Smit, F., & van Marwijk, H. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-59 · Cited by 18
“However, the evidencebase to support such prolonged treatment is poor [5-8] and moreover there is no evidence when to stop AD since most studies restricted their follow up to no longer than 2 years [9].”
BackgroundFactors Associated With Short-Term Disability Episodes
Dewa, C. S., Chau, N. N. S., & Dermer, S. W. (2009) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181bc3f7c · Cited by 18
“This raises the question of possible explanations for this relationship “Is it related to adequate follow-up treatment?” It has been found that treatment in the maintenance phase of depression can significantly reduce the risk of a recurrent episode.(24,25) This raises the question about the extent to which adequate m…”
BackgroundMuskens, E., Eveleigh, R., Lucassen, P., van Weel, C., Spijker, J., Verhaak, P., Speckens, A., & Voshaar, R. O. (2013) · BMC Family Practice · doi:10.1186/1471-2296-14-6 · Cited by 13
“Although in a recent metaanalysis patients with a single depressive episode showed no difference in relapse rates between abrupt and gradual antidepressant discontinuation [16], we advised a gradual tapering program for the following reasons: 1) abrupt discontinuation may trigger a relapse in patients who suffered fro…”
BackgroundResultBerwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-13893-9 · Cited by 13
Wagner, G. J., Gwokyalya, V., Faherty, L. J., Akena, D. H., Nakigudde, J., Ngo, V. K., McBain, R. K., Ghosh‐Dastidar, B., Beyeza‐Kashesya, J., Nakku, J. E. M., et al. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04014-2 · Cited by 12
“Discontinuation was considered when symptoms were in remission (PHQ-9 5) for 6 months [39], and if the mother was at least 6 months post-partum, given the heightened risk of depression post-partum and in the event that she had a miscarriage or abortion.”
Hyman, S. E., Parikh, R., Collins, P. Y., & Patel, V. (2016) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0426-7_ch4 · Cited by 14
Long-Term Treatment of Mood Disorders
Nolen, W. A., & Grunze, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00004-x · Cited by 12
Licht, R. W. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.12.009 · Cited by 11
“However, the number of studies evaluating the preventive potentials of antidepressants beyond one year is scarce (Geddes et al., 2003; Kaymaz et al., 2008).”
BackgroundMethodDurgam, S., Chen, C., Migliore, R., Prakash, C., & Thase, M. E. (2019) · Depression and Anxiety · doi:10.1002/da.22872 · Cited by 11
Klein, N. S., Wijnen, B. F. M., Lokkerbol, J., Buskens, E., Elgersma, H. J., van Rijsbergen, G. D., Slofstra, C., Ormel, J., Dekker, J., de Jong, P. J., et al. (2019) · BJPsych Open · doi:10.1192/bjo.2018.81 · Cited by 12
“30 and 0.48 compared withdiscontinu-ing antidepressants and switching to placebo (for meta-analyses, see Borges et al , Geddes et al , Glue et al and Kaymaz et al 5 – 8 ).”
InfluentialShelton, R. C. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.05 · Cited by 12
Two-mode K-spectral centroid analysis for studying multivariate longitudinal profiles
Heylen, J., Mechelen, I. V., Fried, E. I., & Ceulemans, E. (2016) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2016.03.009 · Cited by 6
“, [42,43]).”
Test-retest & familial concordance of MDD symptoms
Kaiser, A. J. E., Funkhouser, C. J., Mittal, V. A., Walther, S., & Shankman, S. A. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113313 · Cited by 11
Duffy, L., Lewis, G., Marston, L., Kendrick, T., Kessler, D., Moore, M., Wiles, N., & Lewis, G. (2024) · Psychological Medicine · doi:10.1017/s0033291723002659 · Cited by 8
“However, the evidence suggest that patients with one or more previous episodes have higher risk of relapse than patients with a first episode irrespective of treat-ment (Geddes et al., 2003; Kaymaz et al., 2008).”
Differing antidepressant maintenance methodologies
Safer, D. J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.021 · Cited by 9
McBain, R. K., Mwale, O., Ruderman, T., Kayira, W., Connolly, E., Chalamanda, M., Kachimanga, C., Khongo, B. D., Wilson, J., Wroe, E. B., et al. (2021) · Trials · doi:10.1186/s13063-021-05601-1 · Cited by 9
“Discontinuation will be considered if symptoms are in remission for 9 months [54].”
Backgroundvon Knorring, J., Baryshnikov, I., Jylhä, P. J., Talaslahti, T., Heikkinen, M. E., & Isometsä, E. T. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05390-8 · Cited by 8
“Other studies also stress the effectiveness of treatment early in illness [63, 72], that a greater illness burden reflects on the treatment required, and that results diminish for each treatment step needed [60, 66].”
BackgroundBerwian, I. M., Tröndle, M., de Miquel, C., Ziogas, A., Stefanics, G., Walter, H., Stephan, K. E., & Huys, Q. J. M. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.05.001 · Cited by 10
“The choice of whether to discontinue an antidepressant medication plays an important role in this setting because relapses frequently follow discontinuation: around one third of those who discontinue antidepressant medication suffer a relapse within months of discontinuation (6,7,8,9,10).”
The Long-Term Management of Major Depressive Disorders
Shelton, R. C., & Hollon, S. D. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.434 · Cited by 7
“[32]).”
Høstmælingen, A., Ulvenes, P., Nissen‐Lie, H. A., Eielsen, M., & Wampold, B. E. (2021) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2561 · Cited by 7
Metadata
- Authors
- Kaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A.
- Affiliations
- Maastricht University (NL)
- ORCID
- Loonen, Anton J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-09-30
- Volume
- 69
- Issue
- 9
- Pages
- 1423-1436
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2118822483
- Cited by
- 135
- References
- 65
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 2 · 2021: 13 · 2020: 9 · 2019: 10 · 2018: 3 · 2017: 7 · 2016: 15 · 2015: 10 · 2014: 7 · 2013: 7 · 2012: 11
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, relapse prevention, antidepressant discontinuation, recurrent depression, selective serotonin reuptake inhibitors, tricyclic antidepressants, preventive effect, treatment resistance
- MeSH terms
- Acute Disease, Antidepressive Agents, Tricyclic, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Humans, Long-Term Care, Recurrence, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Retreatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.